Company intelligence / Profile preview

IBEX Therapeutics SA

Conthey, Valais, Switzerlandibextx.ch ↗

Ownership: Private
Development stage: Preclinical

Overview

IBEX Therapeutics SA develops innovative mouthwash and related products based on medicinal plant extracts, targeting the prevention and treatment of chemoradiotherapy-induced oral mucositis and candidiasis in cancer patients. The company leverages a patented technology licensed from PHARMALP SA, with pre-formulas developed as phytomedicines or food supplements. Clinical proof-of-concept targeted within three years of founding.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Plant-derived biological products (phytomedicines)Oral topical therapies
Industry: Biotech

Drug pipeline

1 asset

Willowherb extract formulation

Pre-clinical

Indications: Oral mucositis, Oral candidiasis

Partnerships

PHARMALP SA (patent/license holder)

Beyond the preview

Go deeper on IBEX Therapeutics SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBEX Therapeutics SA.

Explore the full profile